Wall Street analysts predict that AstraZeneca plc (NYSE:AZN) will announce sales of $5.76 billion for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for AstraZeneca’s earnings. The lowest sales estimate is $5.37 billion and the highest is $6.12 billion. AstraZeneca reported sales of $5.59 billion during the same quarter last year, which would suggest a positive year over year growth rate of 3%. The business is expected to announce its next earnings results before the market opens on Friday, February 2nd.

On average, analysts expect that AstraZeneca will report full-year sales of $5.76 billion for the current fiscal year, with estimates ranging from $20.03 billion to $22.48 billion. For the next fiscal year, analysts forecast that the company will post sales of $22.07 billion per share, with estimates ranging from $20.47 billion to $23.93 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover AstraZeneca.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the firm earned $1.32 EPS. The company’s revenue was up 9.4% compared to the same quarter last year.

Several research firms recently commented on AZN. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. BMO Capital Markets set a $38.00 price target on shares of AstraZeneca and gave the company a “buy” rating in a research report on Wednesday. Cowen reiterated a “hold” rating and issued a $37.00 price target on shares of AstraZeneca in a research report on Tuesday, October 17th. Credit Suisse Group upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. Finally, BNP Paribas upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $34.20.

Shares of AstraZeneca (AZN) opened at $35.65 on Friday. AstraZeneca has a 12-month low of $26.51 and a 12-month high of $35.92. The company has a market cap of $89,648.45, a price-to-earnings ratio of 8.45, a P/E/G ratio of 3.39 and a beta of 0.72. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72.

A number of institutional investors have recently made changes to their positions in AZN. WFG Advisors LP raised its position in AstraZeneca by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after buying an additional 984 shares during the last quarter. Valeo Financial Advisors LLC purchased a new position in AstraZeneca during the 3rd quarter worth $133,000. Quadrant Capital Group LLC raised its position in AstraZeneca by 18.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after buying an additional 846 shares during the last quarter. Wealthcare Advisory Partners LLC purchased a new position in AstraZeneca during the 3rd quarter worth $184,000. Finally, FTB Advisors Inc. raised its position in AstraZeneca by 3.2% during the 2nd quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock worth $197,000 after buying an additional 200 shares during the last quarter. Institutional investors own 14.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/13/5-76-billion-in-sales-expected-for-astrazeneca-plc-azn-this-quarter.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.